Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers N > Headlines for NPS Pharmaceuticals Inc. > News item |
NPS at market outperform by JMP
NPS Pharmaceuticals was rated at market outperform with a $22 price target by JMP Securities analyst Charles C. Duncan on the company's mixed financial results. NPS' fourth-quarter 2005 results missed JMP's expectations on top and bottom but beat consensus on the bottom line. Revenues of $4.3 million was below the analyst's estimate of $5.3 million and consensus of $4.9 million. Shares of the Salt Lake City pharmaceutical company were down 2 cents, or 0.14%, at $13.92 on volume of 549,601 shares versus the three-month running average of 549,416 shares. (Nasdaq: NPSP)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.